Experts break down key multiple myeloma data and trends from the 23rd Annual IMS Meeting.
Commentary|Videos|June 15, 2025
Dr Dimopoulos on Elranatamab Plus Daratumumab and Lenalidomide in Myeloma
Author(s)Meletios A. Dimopoulos, MD
Fact checked by: Ashling Wahner , Chris Ryan
Meletios A. Dimopoulos, MD, discusses efficacy and safety findings with elranatamab plus daratumumab and lenalidomide in newly diagnosed multiple myeloma.
Advertisement
Meletios A. Dimopoulos, MD, a professor and chairman in the Department of Clinical Therapeutics at the National and Kapodistrian University of Athens School of Medicine, discussed efficacy and safety findings from part 1 of the MagnetisMM-6 trial (NCT05623020), which is investigating elranatamab-bcmm (Elrexfio) plus daratumumab (Darzalex) and lenalidomide (Revlimid) in patients with newly diagnosed multiple myeloma.
Advertisement
Related to this article
First-line IO-based combination regimens were increasingly used and associated with longer observed survival in advanced renal cell carcinoma.
Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ESMO 2026.
The top 5 OncLive TV videos of the week.
The FDA approved atezolizumab plus chemo for stage III colon cancer, cleared a tucatinib-based maintenance regimen for advanced breast cancer, and more.
Experts spotlight the gastrointestinal cancer presentations they’re most excited to see at the 2026 ESMO Congress.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Experts break down key lung cancer data and trends from the IASLC 2026 World Conference on Lung Cancer.
Advertisement
Advertisement
Trending on OncLive
1
Dr Fradley on Real-World Atrial Fibrillation and Cardiovascular Outcomes in CLL
2
Earlier CAR T-Cell Therapy Use Highlights Sequencing and Access Considerations in Myeloma
3
CDK4/6 Inhibitors Anchor First-Line Metastatic Breast Cancer Care, But Oral SERDs May Fall Short
4
Poll Results Highlight Breast Cancer Abstracts of Interest at ESMO 2026
5